WELL Health Technologies Valuation
Is WELL undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of WELL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: WELL (CA$5.14) is trading below our estimate of fair value (CA$29.25)
Significantly Below Fair Value: WELL is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for WELL?
Key metric: As WELL is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is WELL's PE Ratio? | |
|---|---|
| PE Ratio | 17.4x |
| Earnings | CA$73.43m |
| Market Cap | CA$1.25b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.7x |
| Enterprise Value/EBITDA | 14.3x |
| PEG Ratio | -1x |
Price to Earnings Ratio vs Peers
How does WELL's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 29.3x | ||
AND Andlauer Healthcare Group | 25.7x | n/a | CA$1.7b |
VMD Viemed Healthcare | 33x | 49.4% | CA$311.8m |
SIA Sienna Senior Living | 45.3x | n/a | CA$1.4b |
EXE Extendicare | 13.4x | n/a | CA$842.2m |
WELL WELL Health Technologies | 17.4x | -17.4% | CA$1.3b |
Price-To-Earnings vs Peers: WELL is good value based on its Price-To-Earnings Ratio (17.4x) compared to the peer average (29.3x).
Price to Earnings Ratio vs Industry
How does WELL's PE Ratio compare vs other companies in the North American Healthcare Industry?
| 6 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 6 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: WELL is good value based on its Price-To-Earnings Ratio (17.4x) compared to the North American Healthcare industry average (25.6x).
Price to Earnings Ratio vs Fair Ratio
What is WELL's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 17.4x |
| Fair PE Ratio | 16.9x |
Price-To-Earnings vs Fair Ratio: WELL is expensive based on its Price-To-Earnings Ratio (17.4x) compared to the estimated Fair Price-To-Earnings Ratio (16.9x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | CA$5.14 | CA$7.68 +49.5% | 19.5% | CA$10.00 | CA$5.25 | n/a | 15 |
| Nov ’25 | CA$4.39 | CA$7.55 +71.9% | 19.8% | CA$10.00 | CA$5.00 | n/a | 15 |
| Oct ’25 | CA$4.40 | CA$7.61 +73.0% | 19.6% | CA$10.00 | CA$5.00 | n/a | 15 |
| Sep ’25 | CA$4.50 | CA$7.61 +69.2% | 19.6% | CA$10.00 | CA$5.00 | n/a | 15 |
| Aug ’25 | CA$4.70 | CA$7.52 +60.0% | 21.3% | CA$10.00 | CA$4.75 | n/a | 14 |
| Jul ’25 | CA$4.71 | CA$7.52 +59.6% | 21.3% | CA$10.00 | CA$4.75 | n/a | 14 |
| Jun ’25 | CA$3.75 | CA$7.45 +98.7% | 20.8% | CA$10.00 | CA$4.75 | n/a | 15 |
| May ’25 | CA$3.61 | CA$7.39 +104.7% | 20.5% | CA$10.00 | CA$4.75 | n/a | 16 |
| Apr ’25 | CA$3.67 | CA$7.45 +103.1% | 22.0% | CA$11.00 | CA$4.75 | n/a | 16 |
| Mar ’25 | CA$4.19 | CA$7.44 +77.6% | 22.2% | CA$11.00 | CA$4.75 | n/a | 17 |
| Feb ’25 | CA$3.79 | CA$7.69 +102.8% | 22.5% | CA$11.00 | CA$4.75 | n/a | 16 |
| Jan ’25 | CA$3.85 | CA$7.87 +104.3% | 20.4% | CA$11.00 | CA$5.25 | n/a | 15 |
| Dec ’24 | CA$3.90 | CA$7.87 +101.7% | 20.4% | CA$11.00 | CA$5.25 | n/a | 15 |
| Nov ’24 | CA$3.68 | CA$8.21 +123.2% | 19.9% | CA$12.00 | CA$5.50 | CA$4.39 | 14 |
| Oct ’24 | CA$4.15 | CA$8.21 +97.9% | 19.9% | CA$12.00 | CA$5.50 | CA$4.40 | 14 |
| Sep ’24 | CA$4.76 | CA$8.21 +72.6% | 19.9% | CA$12.00 | CA$5.50 | CA$4.50 | 14 |
| Aug ’24 | CA$4.56 | CA$8.30 +82.1% | 22.7% | CA$13.50 | CA$5.50 | CA$4.70 | 14 |
| Jul ’24 | CA$4.75 | CA$8.20 +72.6% | 23.3% | CA$13.50 | CA$5.50 | CA$4.71 | 14 |
| Jun ’24 | CA$5.11 | CA$8.25 +61.4% | 22.5% | CA$13.50 | CA$5.50 | CA$3.75 | 15 |
| May ’24 | CA$5.78 | CA$8.00 +38.4% | 25.0% | CA$13.50 | CA$5.00 | CA$3.61 | 14 |
| Apr ’24 | CA$4.86 | CA$7.96 +63.8% | 26.0% | CA$13.50 | CA$5.00 | CA$3.67 | 13 |
| Mar ’24 | CA$4.33 | CA$7.83 +80.8% | 27.0% | CA$13.50 | CA$5.00 | CA$4.19 | 13 |
| Feb ’24 | CA$3.67 | CA$7.70 +109.7% | 26.9% | CA$13.50 | CA$5.00 | CA$3.79 | 14 |
| Jan ’24 | CA$2.84 | CA$7.66 +169.7% | 27.1% | CA$13.50 | CA$5.00 | CA$3.85 | 14 |
| Dec ’23 | CA$3.12 | CA$7.66 +145.5% | 27.1% | CA$13.50 | CA$5.00 | CA$3.90 | 14 |
| Nov ’23 | CA$3.01 | CA$7.96 +164.6% | 23.4% | CA$13.50 | CA$6.00 | CA$3.68 | 14 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
NeuPath Health
CA$9.0m
Provides chronic pain management services in Canada.
NPTH
CA$0.17
7D
6.3%
1Y
9.7%
Medical Facilities
CA$369.6m
Through its subsidiaries, owns and operates specialty hospitals and ambulatory surgery center in the United States.
DR
CA$15.55
7D
3.2%
1Y
79.1%
Carebook Technologies
CA$6.2m
Engages in the development and commercialization of digital health platforms for assessments, reporting, and targeted solutions in Canada, the United States, Europe, Latin America, Asia, and internationally.
CRBK
CA$0.05
7D
-37.5%
1Y
-28.6%